Glucagon-like peptide 1 receptor agonists and uses thereof
US11045522B2 · kind B2 · utility
1Cited by
8References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 21, 2018 |
| Grant date | Jun 29, 2021 |
| Priority date | — |
| Expiry date | Sep 21, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides modified glucagon-like peptide 1 (GLP1) polypeptides, fusion proteins comprising modified GLP1 polypeptides, and methods of use thereof. In various embodiments of the invention, the fusion proteins are GLP1 receptor agonists that comprise a modified GLP1 fused to a stabilizing domain. In some embodiments, the fusion proteins comprising modified GLP1 are useful for treating or ameliorating a symptom or indication of a disorder such as obesity and diabetes.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.